Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess et al. · CA A Cancer Journal for Clinicians · 2017 · 2.3K citations · Full text

Medicine, Oncology, Surgery +17

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Whole-genome landscapes of major melanoma subtypes

Nicholas K. Hayward, James S. Wilmott, Nicola Waddell et al. · Nature · 2017 · 1.5K citations · Full text

Medicine, Genetics, Molecular Genetics +14

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

Felicity Newell, Yan Kong, James S. Wilmott et al. · Nature Communications · 2019 · 340 citations · Full text

Medicine, Genetics, Oncology +17